Combined Emrosi™ (DFD-29) Phase 3 Efficacy Data Reported
Journey Medical’s FDA-approved Emrosi (DFD-29, 40 mg minocycline hydrochloride modified-release) is now available in the United States for adults...
Jon Napitupulu
Arcutis Presents New ZORYVE Long-Term Atopic Dermatitis Data
Arcutis Biotherapeutics reported new Phase 3 and long-term extension data showing its topical PDE4 inhibitor, Zoryve (roflumilast) cream 0.15%...
SciSparc Announces Acquisition, Transfers Pharma Portfolio
SciSparc has closed a transaction to take a controlling stake in Neurothera Labs Inc., a TSX Venture–listed vehicle that...
Genenta & Anemocyte Announce New DNA Production Partnership
Genenta Science and Anemocyte have expanded their partnership to deliver an off-the-shelf lentiviral vector plasmid DNA platform, making Genenta’s...
Health Canada Grants Authorization for Leqembi Alzheimer Drug
Health Canada has granted a Notice of Compliance with Conditions for Leqembi (lecanemab) for adults with mild cognitive impairment...
Novartis Acquires Avidity to Strengthen Neuroscience Pipeline
Novartis has agreed to acquire Avidity Biosciences for $12 billion in cash, consolidating control of a late-stage pipeline built...
Galapagos In Vitro Data Suggests Unique TYK2 Inhibitor
Galapagos will present new in vitro pharmacology data for its selective TYK2 inhibitor, GLPG3667, at ACR Convergence 2025 in...
Rani Therapeutics Closes Oversubscribed $60.3M Placement
Rani Therapeutics has closed a $60.3 million oversubscribed private placement led by Samsara BioCapital, structured as common stock and...
Sobi Data at ACR 2025 Highlights Advancing Rare Disease Care
Sobi North America is spotlighting 15 presentations at ACR Convergence 2025, featuring new Phase 3 analyses for its investigational...
A Breakthrough in Immunology: Novartis’ New Autoimmune Data
Novartis will deliver 27 presentations at ACR Convergence 2025, headlined by late-breaking, pivotal Phase III results from the replicate...